To compare bleeding and clinical events of patients with stable angina or silent ischemia undergoing percutaneous coronary intervention (PCI) treated with unfractionated heparin (UFH) or bivalirudin.
| INTRODUCTION
The current anticoagulation strategy in patients with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) varies widely based on operator and regional preferences. 1 Contemporary practice for these procedures includes the combined administration of oral anti-platelet agents and intravenous anticoagulation with either unfractionated heparin (UFH) or bivalirudin. 2 Current guidelines list both of these anticoagulants as having a Class I indication for patients undergoing PCI. 2, 3 Although there are several studies and meta-analyses that have compared the use of UFH with bivalirudin in patients with acute coronary syndrome (ACS) undergoing PCI, there is limited data comparing clinical outcomes in patients with stable CAD undergoing PCI. 4, 5 In the Intracoronary Stenting and Antithrombotic RegimenRapid Early Action for Coronary Treatment 3 trial (ISAR-REACT 3), patients with stable and unstable angina undergoing PCI had significantly higher major and minor bleeding events with UFH. 6 However, the dose of UFH administered through this trial was substantially higher than in contemporary practice (140 units/kg given as a bolus), which may have contributed to the increased bleeding rates.
The influence of the arterial access site on bleeding complications is increasingly scrutinized. Meta-analysis conducted by Mina et al, suggested bivalirudin was associated with fewer bleeding events only when femoral access was employed, whereas radial access bleeding was only reduced with the utilization of UFH among patients with ACS. 7 Most recently, the large scale randomized superiority trial Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX Access) compared radial to femoral approaches in 8404 ACS patients undergoing PCI.
Radial access significantly reduced net clinical events by way of lower all-cause mortality and major bleeding. 8 Additionally, other contemporary trials have reported on the impact of access sites in patients undergoing primary PCI. 9, 10 The aim of the present study was to compare bivalirudin with UFH in patients with stable CAD undergoing PCI on dual anti-platelet therapy (DAPT). An exploratory sub-analyses was also conducted to assess the impact of transradial versus transfemoral access.
| METHODS

| Study design and population
The STable Angina Therapy with bivalirudin or UFH for patientS Weight-adjusted UFH was administered as an intravenous bolus (70 IU/kg) to achieve an activated clotting time (ACT) of 250-300 sec with the HemoTec® device. ACT was checked following administration of the bolus and every 20 min during the procedure to ensure that the ACT was at the target level. Bivalirudin was administered as an intravenous bolus (0.75 mg/kg) followed by an infusion (1.75 mg/kg/h) for the remaining duration of the PCI. ACT levels were checked after the bolus administration of bivalirudin to ensure that the ACT was >250 sec. An additional bolus was given if the ACT was <250 sec. In patients with creatinine clearance <30 mL/min, bivalirudin infusion rate was reduced to 1.0 mg/kg/h; the infusion was further reduced to 0.25 mg/kg/h for patients on hemodialysis.
Sheath removal was performed 2 h after discontinuation of the bivalirudin infusion or when the ACT was <180 sec in patients randomized to UFH. Femoral and radial access sites were monitored by blinded study coordinators immediately after the procedure, before and after sheath removal and prior to discharge.
Each subject was evaluated at the index hospitalization and at 30 days after. Data was collected by blinded study personnel at each follow-up encounter. Study data were collected and managed using
Research Electronic Data Capture (REDCap) electronic data capture tools hosted at Stony Brook University. 11 Investigators conducted random audits against the data at different time points during the study's progress to crosscheck collected data. All primary and secondary endpoints were adjudicated by members of an independent Clinical Events Committee, who were blinded to treatment assignments. Safety endpoints were monitored by members of a Data Safety and Monitoring Board who had full access to all aspects of the study data and documentation.
| Study outcomes and statistical analysis
The primary endpoint of the study was cumulative bleeding occurrence within 30 days of index hospitalization as defined by the
Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical
Events (REPLACE)-2 trial definition. 12 Major bleeding was defined as intracranial, intraocular, or retroperitoneal hemorrhage, clinically overt blood loss resulting in a decrease in Hg of more than 3 g/dL, any decrease Two-hundred-sixty enrolled patients underwent PCI and were randomized for treatment with either UFH (n = 123) (47%) or bivalirudin (n = 137) (53%) (Figure 1 ). On December 19, 2013, after interim analysis of the data, the DSMB concurred and recommended to stop recruitment for futility. The DSMB did not identify any safety concerns for the patients enrolled in the trial and while further review of the data was conducted, the Institutional Review Board was informed that recruitment in the trial was suspended.
| Clinical and angiographic characteristics
There were no significant differences between the baseline demographic characteristics of patients enrolled in the two treatment LIMA ET AL.
| 179 groups (Table 1) . A lower left ventricular ejection fraction (52.4% vs 56.6%, P = 0.008) was observed among patients randomized to UFH (Table 2) . Femoral access was more commonly used in both groups (71.5% and 77.8%, respectively), with near concordant closure device rates. There were no significant differences in angiographic and lesion characteristics between the two groups ( Table 2) . The left anterior descending artery and its branches were the most commonly treated coronary territories, followed by the left circumflex artery and right coronary artery.
| Bleeding events
A baseline National Cardiovascular Data Registry® (NCDR) CathPCI
Bleeding Risk Score percent was calculated for all patients in the study. 14 There was no significant difference in baseline bleeding risk scores between patients randomized to UFH or bivalirudin (1.4% ± 1.2 vs 1.6% ± 1.8, respectively, P = 0.17) ( Table 1) . From index-hospitalization up to 30 days follow-up there was no difference in the primary endpoint of the study, which occurred in 7.3% of patients randomized to UFH and 10.9% of patients randomized to bivalirudin (P = 0.31) ( Table 3 ). Major bleeding rates from index-hospitalization up to 30 days follow-up was similar in the UFH and bivalirudin groups (2.4% and 5.8% respectively, P = 0.174) ( Table 3) .
Patients treated via femoral access had numerically higher bleeding rates which was not statistically significant (P = 0.285). There was also no significant difference between the UFH and bivalirudin group among patients treated via femoral versus radial access (Figure 2 ).
| Clinical events
Bivalirudin compared with UFH resulted in significantly increased MACCE rates (3.5% vs 0%, P = 0.032). All of these events were accrued among patients treated with bivalirudin via the femoral access, predominantly caused by MI and cardiac death (Figure 2 ). However, statistically there was no significant difference in MACCE between access sites (P = 0.183, Figure 2 ). Stent thrombosis rates were low and similar in both groups. Two patients in the bivalirudin cohort and none in UFH cohort experienced early-stent thrombosis from indexhospitalization to 30-days (1.46% vs 0%, P = 0.50).
NACE occurred more frequently among patients randomized to bivalirudin (8.8% vs 2.4%, P = 0.029). When assessed by access site, femoral approach demonstrated higher rates of NACE among the bivalirudin cohort compared to UFH (11.4% vs 2.3%, Figure 2 ). There was no overall difference between femoral and radial approach in regard to NACE (P = 0.810) (Figure 2 ). 
| DISCUSSION
The results of STATUS-PCI study showed that in patients with stable CAD undergoing PCI with either UFH or bivalirudin and contemporary use of DAPT: (i) there was no significant difference in bleeding complications at 30 days; (ii) there was a significant increase in MACCE and NACE rates among patients treated with bivalirudin; (iii) bivalirudin was associated with increased odds for NACE in multivariate predictor modeling; (iv) radial access was associated with a numerically lower rate of bleeding complications when compared with femoral access;
and (v) radial access and heparin use in multivariate modeling demonstrated the most favorable odds for decreasing bleeding.
Despite its limitations, UFH it still considered a Class I indication for anticoagulation in patients undergoing PCI. 15 Recent meta-analyses have demonstrated similar MACE and NACE rates between bivalirudin and UFH (particularly when accounting for concomitant GP IIb/IIIa inhibitors) among higher acuity ACS patients undergoing PCI via transradial approach, and using more potent antiplatelet therapy. 7, 16, 17 However, previous randomized trials that enrolled mainly patients with ACS demonstrated a significant reduction of access site and non-access site bleeding complications in patients treated with bivalirudin as compared with patients treated with UFH and GP IIb/IIIa inhibitors. The cohort of stable and unstable angina patients in the ISAR-REACT 3 study
showed that the administration of bivalirudin was associated with lower bleeding rates when compared to UFH. 18 However, it is important to note that the dose of UFH was quite high (140 U/Kg) and patients that had received a lower dose (100 U/Kg) showed similar rates of major bleeding. 18 Two recent studies performed in stable patients deemed to be at an increased bleeding risk have shown conflicting results. The
Novel Approaches for Preventing or Limiting Events (NAPLES) III Trial
randomized 837 consecutive, increased bleeding risk, biomarkernegative patients undergoing PCI via the femoral artery to either the recommended dose of UFH or bivalirudin. 19 In-hospital major bleeding occurred in 2.6% in the UFH group versus 3.3% in the bivalirudin group (P = 0.54). The rate of major and minor bleeding, access site bleeding requiring intervention and clinically overt bleeding were also similar in both groups. 19 The Anti-Thrombotic Strategy for Reduction of
Myocardial Damage During Angioplasty-Bivalirudin versus Heparin
Study (ARMYDA-7 BIVALVE) randomized 401 patients considered to be at high bleeding risk to bivalirudin or UFH (75 IU/kg) during PCI. 20 Although the study showed no difference in 30-day MACCE rates between the two arms, there was a significant reduction in any bleeding or access-site complications after PCI in patient randomized to bivalirudin (1.5% vs 9.9%, P < 0.0001).
20
It is important to note that although the ARMYDA-7 BIVALVE study enrolled patients with a variety of clinical syndromes, the large majority (69-73%) had stable angina and 98% underwent the procedure via the femoral artery. 20 In contrast, this study enrolled 100% of patients with stable angina and utilized radial access in over 25% of the study population with similar distribution between bivalirudin and UFH. The results showed no Acute stent thrombosis has been a source of concern for patients undergoing PCI with bivalirudin. A recent meta-analysis by Piccolo and colleagues of 11 trials, including 16 415 patients showed that treatment with bivalirudin was associated with a significantly higher risk of early stent thrombosis (odds ratio 1.80, CI = 1.28-2.52, P = 0.0007) and reduced major bleeding (odds ratio = 0.64; CI = 0.51-0.82, P = 0.0003) when compared to UFH ± GP IIb/IIIa administration. 24 The increased rate of stent thrombosis was previously noted in multiple trials of patients undergoing primary PCI in the setting of an ST-elevation myocardial infarction. In stable patients enrolled in the NAPLES III study, there was no difference in the rates of stent thrombosis (0.5% in both arms). 19 In this study, two patients that were randomized to bivalirudin developed sub-acute stent thrombosis versus none in the UFH group. This overall low rate may be related to the fact that all patients were pretreated with DAPT.
| Limitations
As a single center trial, there are inherent limitation. The outcomes presented here may be secondary to specific practices at Stony Brook University and may not be generalizable. Given that the study was terminated early by the DSMB, the sample size to obtain adequate power for the primary endpoint was not achieved. While this study was powered on the composite endpoint of major and minor bleeding, previous studies have demonstrated that minor bleeding is not associated with major adverse events. In addition, there was a moderate attrition rate over the follow-up period. The study was not powered to investigate the impact of access site associated events
| CONCLUSION
In patients with stable CAD and pre-treated with DAPT, there was no significant difference in bleeding rates with bivalirudin or UFH. There was, however, a significant increase in MACCE with the use of bivalirudin. Bivalirudin was associated with higher odds for NACE among stable ischemic heart disease.
